Table 1 Demographic and clinical data from (a) cohort 1 and (b) cohort 2. Values are expressed as mean (range)
(a) Cohort 1 | SCD | Probable AD | |||
N | 30 | 30 | |||
Age | 57 (38–78) | 69 (48–80) | |||
Gender (m/f) | 18/12 | 11/19 | |||
At least one APOE ε4 allele | 29.6% | 57.1% | |||
MMSE | 28.48 (25–30) | 19 (9–29) | |||
N-224 (pg/ml) | 65 (12–184) | 194 (33–704) | |||
Aβ42 (pg/ml) | 1052 (656–1550) | 597 (304–810) | |||
T-tau (pg/ml) | 260 (68–527) | 711 (239–1776) | |||
P-tau181 (pg/ml) | 47 (12–92) | 93 (42–252) | |||
(b) Cohort 2 | Control | SCD | MCI | AD | Non-AD |
N | 539 | 195 | 232 | 137 | 253 |
Age | 72 (41–88) | 71 (60–81) | 72 (60–81) | 74 (52–88) | 68 (39–87) |
Gender (m/f) | 185/354 | 92/103 | 133/99 | 49/88 | 157/96 |
At least one APOE ε4 allele | 30.8% | 39.9% | 47.8% | 68.1% | 31.8% |
N-224 (pg/ml) | 63 (4–1251) | 53 (6–230) | 71 (6–488) | 119 (7–666) | 50 (6–483) |
Aβ42/40 (pg/ml) | 0.12 (0.03–0.23) | 0.11 (0.04–0.20) | 0.09 (0.03–0.21) | 0.06 (0.02–0.09) | 0.11 (0.02–0.19) |
T-tau (pg/ml) | 324 (100–1297) | 349 (89–1658) | 420 (46–1427) | 652 (265–1448) | 325 (112–926) |
P-tau181 (pg/ml) | 44 (15–240) | 54 (7–256) | 72 (14–257) | 122 (18–251) | 42 (13–179) |